Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-07-17
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well atezolizumab and cobimetinib work in treating patients
with non-small cell lung cancer that has spread to other places in the body (metastatic), has
come back (recurrent), or does not respond to treatment (refractory). Immunotherapy with
monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Cobimetinib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving
atezolizumab and cobimetinib may work better in treating patients with non-small cell lung
cancer.